HypertensionNCT05131074
Collabree: A Remote Intervention to Improve the Regularity of Medication Intake
A study testing Collabree Mobile Phone Application Medication Adherence Booster and Collabree Mobile Phone Application Medication Adherence Booster (simplified version) in people with Hypertension and Medication Adherence, run by Anjali Raja Beharelle at 1 site in Switzerland.
Trial summary
This is a clinical study to improve the regularity of medication intake for high blood pressure. Adult women and men who are over 50 years old, who have received a prescription drug for high blood pressure from MediService, and who have to take at least 4 tablets per day (of which at least 1 dose of medication per day… Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Hypertension, Medication Adherence
- What is being tested?
- Collabree Mobile Phone Application Medication Adherence Booster and Collabree Mobile Phone Application Medication Adherence Booster (simplified version)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 144 participants
- Where
- 1 siteSwitzerland
- Study dates
- 10 Mar 2022to 24 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Informed consent as documented by signature.
- Over 50 years of age on date of randomization.
- Patient received prescription medicine against hypertension by post from MediService.
- Prescribed a therapy against hypertension consisting of 4 or more tablets taken per day. At least 1 dose of medication per day must be against hypertension.
- Participant administers their own medications.
- Participant owns a smartphone with a data plan or constant internet access during the study reporting events and at home to use the application.
- Minimal required smartphone operating system is iOS 12 and Android 8 (Oreo).
- Adequate communication in German or Swiss-German (all study documentation will only be set to the German language).
Who cannot join
- Inability to operate a mobile phone and the Collabree application.
- Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.
- Enrollment of the Sponsor-Investigator, their family members, employees, and other dependent persons.
- Participation in another interventional clinical trial.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Collabree: A Targeted Behavioral Economics-based Remote Intervention to Improve Medication Adherence in Patients With Hypertension
This is a clinical study to improve the regularity of medication intake for high blood pressure. Adult women and men who are over 50 years old, who have received a prescription drug for high blood pressure from MediService, and who have to take at least 4 tablets per day (of which at least 1 dose of medication per day is for high blood pressure) can participate in this study.
The investigators intend to examine whether Collabree, a mobile phone application, is effective in supporting patients with hypertension to more successfully following their therapy plan in order to improve the regularity of medication intake.
Read more
The study includes a 90-day intervention phase and a 90-day follow-up. The study does not require any therapy adjustments and no visits to a study center are necessary. The participants conduct the study independently at home. Participants will also fill out questionnaires.
Participants are randomly assigned to one of 3 groups in a ratio of 1: 1: 1. Two of these groups will receive the Collabree mobile phone application.
- Conditions
- Hypertension, Medication Adherence
- Being tested
- Collabree Mobile Phone Application Medication Adherence Booster, Collabree Mobile Phone Application Medication Adherence Booster (simplified version)
- Keywords
- Digital Health, Behavioral Change
- Medical subject headings
- Hypertension, Medication Adherence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collabree Mobile Phone Application Medication Adherence BoosterBehavioural
Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
Collabree Mobile Phone Application Medication Adherence Booster (simplified version)Behavioural
Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group A | Experimental | Patients receive the Collabree mobile phone application with a specific set of functions. Receives: Behavioral: Collabree Mobile Phone Application Medication Adherence Booster |
| Intervention Group B | Experimental | Patients receive the Collabree mobile phone application with a specific set of functions. Receives: Behavioral: Collabree Mobile Phone Application Medication Adherence Booster (simplified version) |
| Control Group | No intervention | Patients will not receive the Collabree application. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Medication Adherence
Difference between intervention Group A and the control group in mean medication adherence at endpoint (i.e. the endpoint visit at 90 days) as measured by pill count.
Measured: 90 days
Secondary outcomes (3)
Medication adherence (3 group comparison)
Mean change from baseline in medication adherence (monitored by pill count) at endpoint for the intervention Group A vs. intervention Group B relative to the control group.
Measured: 90 days
Self-reported medication adherence
Mean change from baseline in in-app medication adherence (defined as the number of medications self-reported as "taken" during the intervention period of 90 days divided by the number of prescribed medications listed in the in-app medication plan in that same time period) at endpoint for the intervention Group A vs. intervention Group B relative to the control group.
Measured: 90 days
Self-assessed medication adherence
Mean change from baseline in the score on the Hill-Bone Scale (German version) questionnaire on medication adherence for the intervention Group A vs. intervention Group B relative to the control group at endpoint. The Hill-Bone Compliance to Blood Pressure Therapy Scale (German) scores can range from 14 to 56. A higher score means worse compliance.
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Nov 2021
- Study start10 Mar 2022
- Primary completion23 Aug 2024
- Study completion24 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 144 participants (actual)
Sponsor and investigators
- Lead sponsor
- Anjali Raja Beharelle
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- MediService AG
- Responsible party
- Sponsor-investigator, Anjali Raja Beharelle, Collabree AG
- Investigators
- Anjali Raja Beharelle, PhD, Principal investigator, Collabree AG
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05131074
- Sponsor's protocol ID
- COLLABREE-RS
- Status last verified
- Feb 2024
- First submitted
- 11 Nov 2021
- Last updated
- 18 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Collabree: A Targeted Behavioral Economics-based Remote Intervention to Improve Medication Adherence in Patients With Hypertension
- ClinicalTrials.gov ID
- NCT05131074
- Acronym / sponsor ID
- COLLABREE-RS
- Conditions
- Hypertension, Medication Adherence
- Keywords
- Digital Health, Behavioral Change
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 144 participants (actual)
- Lead sponsor
- Anjali Raja BeharelleIndustry (pharma, biotech, devices)
- Collaborators
- MediService AG
- Study start
- 10 Mar 2022 (actual)
- Primary completion
- 23 Aug 2024 (actual)
- Study completion
- 24 Nov 2024 (actual)
- First posted
- 23 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a clinical study to improve the regularity of medication intake for high blood pressure. Adult women and men who are over 50 years old, who have received a prescription drug for high blood pressure from MediService, and who have to take at least 4 tablets per day (of which at least 1 dose of medication per day is for high blood pressure) can participate in this study.
The investigators intend to examine whether Collabree, a mobile phone application, is effective in supporting patients with hypertension to more successfully following their therapy plan in order to improve the regularity of medication intake.
The study includes a 90-day intervention phase and a 90-day follow-up. The study does not require any therapy adjustments and no visits to a study center are necessary. The participants conduct the study independently at home. Participants will also fill out questionnaires.
Participants are randomly assigned to one of 3 groups in a ratio of 1: 1: 1. Two of these groups will receive the Collabree mobile phone application.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Intervention Group A | Experimental | Behavioral: Collabree Mobile Phone Application Medication Adherence BoosterPatients receive the Collabree mobile phone application with a specific set of functions. |
| Intervention Group B | Experimental | Behavioral: Collabree Mobile Phone Application Medication Adherence Booster (simplified version)Patients receive the Collabree mobile phone application with a specific set of functions. |
| Control Group | No intervention | –Patients will not receive the Collabree application. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Informed consent as documented by signature.
- Over 50 years of age on date of randomization.
- Patient received prescription medicine against hypertension by post from MediService.
- Prescribed a therapy against hypertension consisting of 4 or more tablets taken per day. At least 1 dose of medication per day must be against hypertension.
- Participant administers their own medications.
Key exclusion criteria (4 listed)
- Inability to operate a mobile phone and the Collabree application.
- Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.
- Enrollment of the Sponsor-Investigator, their family members, employees, and other dependent persons.
- Participation in another interventional clinical trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collabree Mobile Phone Application Medication Adherence BoosterPatients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. | Behavioural | Intervention Group A |
| Collabree Mobile Phone Application Medication Adherence Booster (simplified version)Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. | Behavioural | Intervention Group B |
Primary outcome
Medication Adherence
Time frame: 90 days
Difference between intervention Group A and the control group in mean medication adherence at endpoint (i.e. the endpoint visit at 90 days) as measured by pill count.
3 secondary outcomes
Medication adherence (3 group comparison)
Time frame: 90 days
Self-reported medication adherence
Time frame: 90 days
Self-assessed medication adherence
Time frame: 90 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anjali Raja Beharelle, PhD principal investigator
Collabree AG
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Collabree Mobile Phone Application Medication Adherence Booster and Collabree Mobile Phone Application Medication Adherence Booster (simplified version) in people with Hypertension and Medication Adherence, run by Anjali Raja Beharelle at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Medication Adherence (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.